Fig. 2
From: Gucy1α1 specifically marks kidney, heart, lung and liver fibroblasts
Gucy1α1 levels increase as kidney injury progresses and correlate with key fibrosis markers. (A) qPCR showing Gucy1α1 expression changes over the course of UIR and UUO. Relative expression normalized to 18s, shown as fold change, n = 4 per group, ordinary one-way ANOVA, P *≤0.05, **≤0.01, ***≤0.001, ****≤0.0001 compared to the control. (B-D) Western blotting demonstrating progressive Gucy1α1 elevation accompanying fibrosis progression in both models, images (B and C) and quantification (D). Gucy1α1 signal normalized to Gapdh, n = 4 per group, ordinary one-way ANOVA, P **≤0.01, ***≤0.001, ****≤0.0001 compared to the control. (E and F) Correlation analysis between normalized Pdgfrβ, αSma, Vim levels and Gucy1α1 in the control and UIR (E) and control and UUO (F) models at all experimental timepoints. Pearson r correlation analysis, n = 24 per marker (control, Day 1, Day 4, Day 7, Day 14, Day 28, n = 4 per each group), r values and P as **≤0.01, ***≤0.001, ****≤0.0001 for each pair are shown on the graphs presenting simple linear regression of correlation between Pdgfrβ, αSma, Vim vs. Gucy1α1. Data in scatter plots is presented as mean ± SD.
